🔺 THING — Daily Digest

Published 2026-06-05 17:23 ET · local QWEN3 pipeline · mirror of a private Roth-IRA research tool

Rebalance

DEPLOY $8,000 from cash into 8 fundamentally-confirmed names (dropped RILY/CLFD from the mechanical 4/4)

Current book

Ticker	Shares	Value	Weight

Total $8,000 · cash $8,000 (100.0%)

Proposed actions

Ticker	Action	Shares	Px est	Rationale
AAON	buy	7.0	$135.18	Q1 sales +54%, record $2.13B backlog (+107%) led by BASX data-center liquid-cooling; FY26 guide 40-45%. Cleanest fundamental in the basket.
XMTR	buy	14.0	$81.00	Q1 rev +36%, EPS beat ~20%, +42% on the print; $50M Siemens equity stake + partnership. Real inflection.
HLIT	buy	82.0	$13.54	Broadband rev +43%, FY26 raised, ran ~$11.76->$17 in May; Needham PT $18. Video-sale + buyback cleans the story.
OSCR	buy	47.0	$23.73	Q1 rev $4.65B, net income $679M, FY26 op-income reaffirmed $250-450M, MLR improving. Profitable scale.
SYNA	buy	9.0	$125.97	Q3 EPS $1.09 vs $0.84; Edge-AI/robotics design wins ramping 2027; Rosenblatt PT $180.
OKTA	buy	7.0	$119.17	Classifier rank 0.78 on price action, but only ~9% growth — quality ballast, NOT a parabola. Sized small.
ELVA	buy	76.0	$10.45	Q2 rev +20%, profitable; data-center 800V battery angle + Fortune-500 order. Micro-cap — sized small.
URGN	buy	30.0	$26.87	UGN-103 Phase 3 94.5% durable response, NDA Q3 2026; ZUSDURI launching. Binary biotech — speculative sleeve.

Projected book

Ticker	Shares	Value	Weight
AAON	7.0	$946	11.8%
XMTR	14.0	$1,134	14.2%
HLIT	82.0	$1,110	13.9%
OSCR	47.0	$1,115	13.9%
SYNA	9.0	$1,134	14.2%
OKTA	7.0	$834	10.4%
ELVA	76.0	$794	9.9%
URGN	30.0	$806	10.1%

Total $8,000 · cash $126 (1.6%)

Fresh cash, no holdings -> clean build: no T+1 settlement lock, no GFV risk.

Dropped RILY (restructuring/debt-wall/Nasdaq-compliance distress) + CLFD (Q2 rev -15%, tariff/supply headwinds) vs the mechanical 4/4 screen -- fundamental override the gate can't make.

Deployed ~$7,874, ~$126 residual from whole-share rounding. Cluster caps eyeballed (broad-scan names carry no sector tag); spread across software/health/semis/industrials/biotech.

Doctrine shortlist — 4/4 gate passers

29 of 3548 screened names clear all four entry gates.

#	Ticker	Gates	Cycle	Clf	Regime	Stop-buf
1	OKTA	4/4	2dn	78%	consolidating	15%
2	NXT	4/4	3up	77%	consolidating	21%
3	HLIT	4/4	2dn	75%	consolidating	18%
4	ABCL	4/4	3up	75%	early_parabolic	22%
5	NNBR	4/4	3up	74%	early_parabolic	19%
6	RMBS	4/4	3up	74%	early_parabolic	19%
7	OSCR	4/4	2dn	73%	consolidating	15%
8	ULCC	4/4	3up	71%	consolidating	15%
9	CLFD	4/4	2dn	71%	consolidating	21%
10	AAON	4/4	3up	71%	consolidating	15%
11	LODE	4/4	3up	70%	early_parabolic	17%
12	NVEC	4/4	3up	68%	early_parabolic	16%
13	MASS	4/4	3up	65%	early_parabolic	15%
14	API	4/4	3up	65%	consolidating	16%
15	URGN	4/4	2dn	64%	consolidating	15%
16	DBI	4/4	3up	64%	early_parabolic	15%
17	GHRS	4/4	3up	64%	consolidating	18%
18	URG	4/4	3up	63%	early_parabolic	16%
19	FEIM	4/4	3up	62%	consolidating	17%
20	NMAX	4/4	3up	61%	consolidating	19%
21	PLSE	4/4	3up	59%	consolidating	17%
22	FTK	4/4	3up	59%	early_parabolic	15%
23	XMTR	4/4	2dn	57%	consolidating	15%
24	KPTI	4/4	3up	55%	early_parabolic	20%
25	BTDR	4/4	3up	54%	consolidating	22%
26	ELVA	4/4	2dn	54%	consolidating	19%
27	PAYS	4/4	3up	52%	early_parabolic	17%
28	SYNA	4/4	2dn	51%	consolidating	17%
29	RILY	4/4	2dn	50%	consolidating	21%

Analyst note

The setup — $8,000, zero holdings, bull_confirmed

Fresh $8,000, no positions, regime reads bull_confirmed (conf 1.0). Doctrine is unambiguous here: cash is 100% of book, so the only acceptable move is deploy. And because there's nothing held, this is a clean from-scratch build — no rotation, no T+1 settlement lock, no good-faith-violation risk. The easy part.

What the engine handed me — and why I'm not taking it at face value

The broad scan swept 3,548 liquid names and returned 29 that pass all four gates. The deterministic sizer wanted to spread the $8k roughly equal-weight across the top 10 by conviction. Here's the tell I want you to see before you trust that: 9 of those 10 are labeled `2dn` (wave-2 pullback), every one with cycle confidence pinned at exactly 1.0, and every one calibrating to the same ~26% P(+50%/90d).

That uniformity isn't conviction — it's the model failing to differentiate. The cycle "confidence" is uncalibrated (we proved that in this week's audit), and the calibrated classifier is parked on a flat isotonic step. So the screen is really saying "these are statistically momentum-ish names in a confirmed bull," not "here are 10 distinct moonshots." The gate can't read a 10-K. I can — and that's where this digest earns its space over the local model's "deploy now, no hesitation."

Three camps, after reading the actual tape

Camp 1 — momentum and fundamentals agree (deploy):

AAON `3up` — the cleanest name in the basket. Q1 sales +54% YoY, record $2.13B backlog (+107%), FY26 guide raised to 40–45% growth. The kicker: the backlog surge is BASX liquid-cooling for data centers. This is a real secular tailwind, not a chart artifact.
XMTR — Q1 +36% revenue, EPS beat ~20%, stock +42% on the print, plus a $50M Siemens equity stake + partnership. Genuine inflection in the manufacturing marketplace.
HLIT — Broadband revenue +43%, FY26 outlook raised, ran ~$11.76→$17 in May on the beat (Needham PT $18). The video-business sale + $200M buyback cleans up the story.
OSCR — Q1 revenue $4.65B, net income $679M, FY26 op-income guide reaffirmed at $250–450M, MLR improving. This is profitable scale, not a lottery ticket.
SYNA — Q3 beat (EPS $1.09 vs $0.84), Edge-AI / robotics design wins ramping into 2027, Rosenblatt PT raised to $180.
ELVA — Q2 revenue +20%, profitable, Fortune-500 order, and an explicit data-center / 800V battery angle. Tiny and volatile, so it's sized small — but the order book is real.
URGN — biotech: ZUSDURI approved and launching, UGN-103 Phase 3 94.5% durable response, NDA planned Q3 2026. Higher-variance (catalyst-binary) but a genuine pipeline, not vapor — sized as the speculative sleeve.
OKTA — the quality anchor, and I'll be honest: it guides ~9% growth. The classifier likes its price action (rank 0.78), but this is not a parabola. I'm keeping it as small ballast, not as a moonshot.

Camp 2 — the gate flagged it, the fundamentals say no (I'm cutting):

CLFD — the scan calls it a wave-2 pullback. The tape calls it a downtrend: Q2 sales −15% YoY, management flagging tariff and optical-fiber supply-chain uncertainty. A "pullback" with falling revenue is just a decline with a nice-looking stop. Cut.
RILY (now BRC Group Holdings) — the one a mechanical screen cannot see. Yes, Q1 printed $211M net income — but that's fair-value gains, the company is mid-restructuring, faces a Nasdaq compliance deadline and a 2026–2027 debt wall, and the stock fell ~9% on May 29. A 4/4 here is a volatility artifact on a distressed balance sheet. Hard pass.

My deploy — overlay on the engine

Drop RILY and CLFD; redistribute the freed cash into the eight where momentum and fundamentals agree, tilted toward the blowout-backlog names (AAON, XMTR, HLIT, OSCR, SYNA), with OKTA/ELVA/URGN sized smaller as ballast + speculative sleeve. The structured before/after is in the rebalance table above — ~$7,874 deployed across 8 names, ~$126 residual (whole-share rounding), nothing over ~14%.

Honest footer

Every name calibrates to ~26% P(+50%/90d) — these are roughly 1-in-4 shots. They're sized so no single miss hurts (≤~14% each). The measured edge is the calibrated classifier (gate 2); the Elliott-wave phase is a discipline filter, not alpha (the audit showed the gate's own entry phases hit at/below the base rate out-of-sample).
The classifier was trained on ~558 large/mid-caps but is now scoring ~5,600 names including these small-caps — it's extrapolating. Treat the micro-caps (ELVA, URGN, and the cut RILY) with extra skepticism.
This is recommend, not execute: these are my reads off the current tape; you place the orders in Fidelity. Sources: company 8-Ks/SEC filings, StockTitan, Seeking Alpha, Needham/Rosenblatt notes (all 2026).